DiaMedica Therapeutics Inc

NASDAQ:DMAC   3:59:53 PM EDT
3.27
-0.26 (-7.36%)
Products

Diamedica Therapeutics Announces Positive Interim Results From Phase 2 Redux Study In Ckd

Published: 06/29/2021 11:07 GMT
DiaMedica Therapeutics Inc (DMAC) - Diamedica Therapeutics Announces Positive Interim Results From Phase 2 Redux Study in Ckd.
Diamedica Therapeutics Inc - Results Affirm Biological Activity, Safety and Tolerability of Dm199 Consistent With Porcine Klk1 Product in Asia.
Diamedica - Early Data Indicate Statistically and Clinically Significant Reduction in Uacr Seen in Iga Nephropathy and Hypertensive African Americans.
Diamedica Therapeutics Inc - Study Demonstrates Stable Egfr and Positive Effects on Blood Pressure Across All Cohorts.
Diamedica Therapeutics Inc - Dm199 Was Well Tolerated Across All Cohorts, With No Dm199 Related Severe Adverse Events.